ClinicalTrials.gg
Not yet recruitingNCT07489586Updated Mar 24, 2026

A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration

A Phase 3 interventional study of QL1207H injection and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration (nAMD), sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
356
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the efficacy and safety of QL1207H injection versus aflibercept 8 mg in patients with neovascular age-related macular degeneration. The main question it aims to answer is:

  • Whether the efficacy and safety of QL1207H and aflibercept 8 mg are similar. Participants will receive injection once every 4 weeks for 3 consecutive doses, followed by injection once every 16 weeks at maximum.

Researchers will compare QL1207H group and aflibercept 8 mg group to see if they are similar in improving best corrected visual acuity.

02

Conditions studied

  • Neovascular Age-Related Macular Degeneration (nAMD)
03

In context

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

This study's planned enrollment of 356 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.

Browse Macular Degeneration studies →

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 50 years of age.
  2. Active subfoveal CNV secondary to nAMD, including juxtafoveal lesions that affect the fovea as assessed in the study eye.
  3. Total area of CNV (including both classic and occult components) must comprise greater than 50% of the total lesion area in the study eye.
  4. Presence of IRF and/or SRF affecting the central subfield of the study eye on OCT.
  5. BCVA ETDRS letter score of 78 to 24 in the study eye.

Exclusion criteria

Exclusion Criteria:

  1. Causes of CNV other than nAMD in the study eye.
  2. Total lesion size >12 disc areas; or subretinal hemorrhage that is at least 50% of the total lesion area, or if the blood under the fovea is 1 or more disc areas in size in the study eye.
  3. Scar, fibrosis, or atrophy involving the central subfield in the study eye.
  4. Uncontrolled glaucoma (defined as IOP >25 mmHg despite treatment with antiglaucoma medication) in the study eye.
  5. Myopia of a spherical equivalent of at least 8 diopters in the study eye prior to any refractive or cataract surgery.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
356 participants (estimated)

Study arms

  • Experimental
    QL1207H injection group

    Drug: QL1207H injection

  • Active comparator
    Aflibercept 8 mg group

    Drug: Aflibercept 8 mg

Interventions

  • DrugQL1207H injection

    During the first 8 weeks of the treatment period, the drug will be administered once every 4 weeks for 3 consecutive doses, followed by dosing once every 16 weeks at maximum.

  • During the first 8 weeks of the treatment period, the drug will be administered once every 4 weeks for 3 consecutive doses, followed by dosing once every 16 weeks at maximum.

06

What researchers measure

Primary outcomes

  1. Change from baseline in BCVA at Week 12

    Time frame: Week 12

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Dec 2026, 9 months later.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 9 months is below that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Mar 24, 2026
StartEst.
Mar 2026
Primary completionEst.
Dec 2026
CompletionEst.
Aug 2027
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07489586
Responsible party
Sponsor
First posted
Mar 24, 2026
Start date
Mar 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Aug 2027 (estimated)
Last update
Mar 24, 2026

Study contacts

Wangwang Zhi, Master
Contact
wangwang.zhi@qilu-pharma.com
+86-17761717313

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion